Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

S0833, Modified Total Therapy 3 (TT3) for Newly Diagnosed Patients With Multiple Myeloma (MM): A Phase II SWOG Trial for Patients Aged ≤ 65 Years

Next Previous
Trial Profile

S0833, Modified Total Therapy 3 (TT3) for Newly Diagnosed Patients With Multiple Myeloma (MM): A Phase II SWOG Trial for Patients Aged ≤ 65 Years

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Lenalidomide (Primary) ; Thalidomide (Primary) ; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Enoxaparin sodium; Etoposide; Melphalan
  • Indications Multiple myeloma
  • Focus Pharmacogenomic; Therapeutic Use

Most Recent Events

  • 03 Jan 2013 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
  • 03 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 21 Jul 2011 Additional lead trial investigator (Zonder Jeffrey) identified as reported by Barbara Ann Karmanos Cancer Institute.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top